← Leaderboards
Miguel S Esteves
Massachusetts General Hospital
$8,755,816
Attributed
$13,593,645
Total exposure
7
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.6M · FY2006–24$5M$3.8M$2.5M$1.3M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$17,108,561 · 8
By mechanism
R01$9,405,290 · 4
U01$7,100,747 · 2
R21$602,524 · 2
Top collaborators
- Douglas R Martin14 shared
- Heather L Gray-Edwards5 shared
- Thomas J. Meade5 shared
Others in their field
Top investigators on “Gene Therapy”
- David Heimbrook · Leidos Biomedical Research, Inc.$164,199,916
- Gregory H Reaman · National Childhood Cancer Foundation$155,841,493
- Randall J Bateman · Washington University$122,781,098
- Eric Martin McDade · Washington University$94,632,845
- Ronald G Crystal · Weill Medical College Of Cornell Univ$82,649,124
- Robert B. Diasio · University Of Alabama At Birmingham$73,470,685
Research focus
Gene TherapyLysosomal Storage DiseasesBrainOrganEnzymesMouse ModelMediatingClinical TrialsFelis CatusMagnetic Resonance ImagingAdeno-Associated Viral VectorAffectNervous System DisorderCapsidSandhoff DiseaseSafetyThalamic StructureVectorNeurologicBeta-N-AcetylhexosaminidaseBiodistributionCellsGenesGangliosidoses Gm2
Grant awards (29)
Real-Time Tracking of Gene Therapy by Bioactivated MR contrast Probes$548,624
R01 · FY2024 · NS
Real-Time Tracking of Gene Therapy by Bioactivated MR contrast Probes$659,071
R01 · FY2023 · NS
Real-Time Tracking of Gene Therapy by Bioactivated MR contrast Probes$655,861
R01 · FY2022 · NS
Real-Time Tracking of Gene Therapy by Bioactivated MR contrast Probes$645,047
R01 · FY2021 · NS
Real-Time Tracking of Gene Therapy by Bioactivated MR contrast Probes$629,733
R01 · FY2020 · NS
Whole-body therapy for GM2 gangliosidoses$536,121
R01 · FY2020 · NS
Whole-body therapy for GM2 gangliosidoses$584,327
R01 · FY2019 · NS
Whole-body therapy for GM2 gangliosidoses$589,446
R01 · FY2018 · NS
Whole-body therapy for GM2 gangliosidoses$599,714
R01 · FY2017 · NS
Whole-body therapy for GM2 gangliosidoses$630,300
R01 · FY2016 · NS
Gene Therapy for Neurodegenerative Lysosomal Storage Diseases$493,126
R01 · FY2013 · HD · contact PI
AAV-mediated gene therapy for GM2-gangliodoses$847,727
U01 · FY2012 · NS · contact PI
AAV-mediated gene therapy for GM2-gangliodoses$776,812
U01 · FY2012 · NS · contact PI
Gene Therapy for Neurodegenerative Lysosomal Storage Diseases$506,598
R01 · FY2012 · HD · contact PI
Development of CNS-targeted AAV vectors$322,420
R01 · FY2012 · NS · contact PI
AAV-mediated gene therapy for GM2-gangliodoses$827,235
U01 · FY2011 · NS · contact PI
AAV-mediated gene therapy for GM2-gangliodoses$827,235
U01 · FY2011 · NS · contact PI
Gene Therapy for Neurodegenerative Lysosomal Storage Diseases$501,435
R01 · FY2011 · HD · contact PI
Development of CNS-targeted AAV vectors$322,420
R01 · FY2011 · NS · contact PI
AAV-mediated gene therapy for GM2-gangliodoses$855,961
U01 · FY2010 · NS · contact PI
AAV-mediated gene therapy for GM2-gangliodoses$855,961
U01 · FY2010 · NS · contact PI
Gene Therapy for Neurodegenerative Lysosomal Storage Diseases$527,087
R01 · FY2010 · HD · contact PI
Development of CNS-targeted AAV vectors$325,710
R01 · FY2010 · NS · contact PI
AAV-mediated gene therapy for GM2-gangliodoses$1,054,908
U01 · FY2009 · NS · contact PI
AAV-mediated gene therapy for GM2-gangliodoses$1,054,908
U01 · FY2009 · NS · contact PI
Development of CNS-targeted AAV vectors$328,250
R01 · FY2009 · NS · contact PI
Gene therapy for Ataxia Telangiectasia$176,250
R21 · FY2009 · NS · contact PI
Gene delivery methods for global therapy in the CNS$229,399
R21 · FY2007 · NS · contact PI
Gene delivery methods for global therapy in the CNS$196,875
R21 · FY2006 · NS · contact PI